Autologous bone-marrow stem-cell transplantation for myocardial regeneration.
Implantation of bone-marrow stem cells in the heart might be a new method to restore tissue viability after myocardial infarction. We injected up to 1.5x10(6) autologous AC133+ bone-marrow cells into the infarct border zone in six patients who had had a myocardial infarction and undergone coronary artery bypass grafting. 3-9 months after surgery, all patients were alive and well, global left-ventricular function was enhanced in four patients, and infarct tissue perfusion had improved strikingly in five patients. We believe that implantation of AC133+ stem cells to the heart is safe and might induce angiogenesis, thus improving perfusion of the infarcted myocardium. See Commentary page 11
Stamm
Christof
C
Department of Cardiac Surgery, University of Rostock, 18057, Rostock, Germany.
Westphal
Bernd
B
Kleine
Hans-Dieter
HD
Petzsch
Michael
M
Kittner
Christian
C
Klinge
Heiko
H
Schümichen
Carl
C
Nienaber
Christoph A
CA
Freund
Mathias
M
Steinhoff
Gustav
G
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002317:Cardiovascular Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000628:therapy*
D002317:Cardiovascular Agents